Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.24−0.49 (-3.33%)
Close on Nov 17, 2026Market cap $1.56BP/E 6.2Yield 0.00%
Nurix Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Nurix Therapeutics's revenue for the twelve months ending Aug 31, 2026 was $701.94M, up 738.8% year over year. For fiscal 2025 it was $83.98M, up 54.0% from the year before. The highest annual figure on record is $83.98M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $83.98M | +54.0% |
| FY2024 | Nov 30, 2024 | $54.55M | -29.1% |
| FY2023 | Nov 30, 2023 | $76.99M | +99.3% |
| FY2022 | Nov 30, 2022 | $38.63M | +29.8% |
| FY2021 | Nov 30, 2021 | $29.75M | +66.9% |
| FY2020 | Nov 30, 2020 | $17.82M | -42.7% |
| FY2019 | Nov 30, 2019 | $31.12M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $673.06M | +8426.3% |
| Q2 FY2026CQ2 2026 | May 31, 2026 | $9.04M | -79.5% |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | $6.25M | -66.1% |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | $13.58M | +2.2% |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | $7.89M | -37.3% |
| Q2 FY2025CQ2 2025 | May 31, 2025 | $44.06M | +264.3% |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | $18.45M | +11.3% |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | $13.28M | -12.4% |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | $12.59M | -31.8% |
| Q2 FY2024CQ2 2024 | May 31, 2024 | $12.09M | -60.6% |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | $16.59M | +30.7% |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | $15.16M | +123.5% |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | $18.47M | +71.1% |
| Q2 FY2023CQ2 2023 | May 31, 2023 | $30.68M | +168.3% |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | $12.69M | +31.8% |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | $6.78M | -8.3% |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | $10.79M | +5.3% |
| Q2 FY2022CQ2 2022 | May 31, 2022 | $11.43M | +61.2% |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | $9.62M | +92.0% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | $7.40M | +10.6% |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | $10.25M | +151.0% |
| Q2 FY2021CQ2 2021 | May 31, 2021 | $7.09M | +69.6% |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $5.01M | +75.0% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | $6.69M | +259.2% |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | $4.09M | -61.4% |
| Q2 FY2020CQ2 2020 | May 31, 2020 | $4.18M | -55.7% |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $2.86M | -69.0% |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | $1.86M | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | $10.58M | – |
| Q2 FY2019CQ2 2019 | May 31, 2019 | $9.44M | – |
| Q1 FY2019CQ1 2019 | Feb 28, 2019 | $9.23M | – |
See a number that looks wrong?